# Karyopharm Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/karyopharm-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Natick, US
- Website: www.karyopharm.com
- Total disclosed funding: $60M
- Latest round: Series B (Jul 26, 2013)
- Investors on record: 4

## About

Karyopharm Therapeutics is a biotechnology company focused on developing innovative cancer therapies, particularly through its unique oral Selective Inhibitor of Nuclear Export (SINE) technology.Karyopharm Therapeutics specializes in creating advanced cancer treatments. Founded by Michael Kauffman and Sharon Shacham, the company is headquartered in Natick, US. It went public in November 2013, raising USD 109 mn by offering 6.8 million shares at USD 16 each. The latest funding round was a PIPE, raising USD 165 mn, led by Avidity Partners, with participation from multiple investment firms.Karyopharm Therapeutics Inc. specializes in developing innovative cancer therapies, with a particular focus on oral Selective Inhibitor of Nuclear Export (SINE) technology. Their core product offerings primarily include novel treatments aimed at addressing various oncological conditions, including multiple myeloma and diffuse large B-cell lymphoma (DLBCL). These therapies are designed to target critical mechanisms involved in cancer cell growth and survival, ultimately enhancing treatment efficacy for patients with high unmet medical needs. Karyopharm’s products are marketed to healthcare providers, oncologists, and hospitals across North America, Europe, and select international markets, catering to a client base that includes both healthcare professionals and the patients they treat.Karyopharm's revenue generation model is rooted in the commercialization of its proprietary cancer therapies. The company reported revenue of USD 145.24 mn for the year 2024, with an EBITDA of USD -115.24 mn. Karyopharm engages in direct-to-consumer sales and B2B transactions with healthcare institutions, such as hospitals and specialized clinics. Through these direct sales channels, Karyopharm aims to establish strategic partnerships with healthcare providers to optimize patient access to their innovative therapies.Karyopharm Therapeutics aims to expand its portfolio by launching new products designed to enhance cancer treatment options. The funding raised in the PIPE round will be utilized to support these initiatives as well as to explore entry into new markets. The company is actively seeking to penetrate additional regions in North America and Europe by the end of 2025, enhancing its global reach and improving access to its therapies for patients.

## Funding rounds

- Series B, Jul 26, 2013, $19M — Delphi Ventures, New Leaf Venture Partners, Foresite Capital
- Series B, Apr 17, 2013, $21M — Delphi Ventures
- Series A, Nov 3, 2010, $20M — Bessemer Venture Partners

## Investors

- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B